Skip to main content
SpringerLink
Log in

Antihypertensive Drug Therapy in Patients of African and South Asian Ethnicity: A Systematic Review

  • Chapter
  • First Online:
Ethnic Diversities, Hypertension and Global Cardiovascular Risk

Part of the book series: Updates in Hypertension and Cardiovascular Protection ((UHCP))

  • 347 Accesses

Abstract

Patients of South Asian or African ethnicity have a greater burden of hypertension and diabetes, leading to early target organ damage and premature cardiovascular mortality. This could have important implications for cardiovascular risk management. In this chapter, we systematically review the evidence on the effect of antihypertensive drug treatment on blood pressure, morbidity, and mortality in African and South Asian ethnicity patients. We used the Cochrane systematic review methodology to retrieve trials in electronic databases including Cochrane CENTRAL, PubMed, and Embase from their inception through September 2017. We retrieved 5311 reports that yielded 35 trials with 7 classes of antihypertensive drugs in 25,540 African ethnicity patients. Aside from the well-known blood pressure efficacy of calcium channel blockers and diuretics, with lesser effect of ACE inhibitors and beta-blockers, trials with morbidity and mortality outcomes indicated that lisinopril- and losartan-based therapy were associated with greater incidence of stroke and sudden death in African ancestry patients. In South Asian patients, 2188 reports yielded 17 randomized controlled trials with blood pressure outcomes in 1819 hypertensives. In contrast with the studies in African ethnicity patients, there were no significant differences in blood pressure lowering efficacy between drugs. We retrieved no trials with mortality outcomes in South Asians. The existing evidence indicates that ethnic-specific hypertension management may reduce cardiovascular mortality, but there is an urgent need for evidence-based strategies to reduce hypertension-related cardiovascular mortality in South Asians.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. George J, Mathur R, Shah AD, Pujades-Rodriguez M, Denaxas S, Smeeth L, Timmis A, Hemingway H. Ethnicity and the first diagnosis of a wide range of cardiovascular diseases: associations in a linked electronic health record cohort of 1 million patients. PLoS One. 2017;12:e0178945.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  2. Khan JM, Beevers DG. Management of hypertension in ethnic minorities. Heart. 2005;91:1105–9.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Gu Q, Burt VL, Paulose-Ram R, Yoon S, Gillum RF. High blood pressure and cardiovascular disease mortality risk among U.S. adults: the third National Health and nutrition examination survey mortality follow-up study. Ann Epidemiol. 2008;18:302–9.

    Article  PubMed  Google Scholar 

  4. Martins D, Tareen N, Ogedegbe G, Pan D, Norris K. The relative risk of cardiovascular death among racial and ethnic minorities with metabolic syndrome: data from the NHANES-II mortality follow-up. J Natl Med Assoc. 2008;100:565–71.

    Article  PubMed  Google Scholar 

  5. Cappuccio FP, Oakeshott P, Strazzullo P, Kerry SM. Application of Framingham risk estimates to ethnic minorities in United Kingdom and implications for primary prevention of heart disease in general practice: cross sectional population based study. BMJ. 2002;325:1271.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Brewster LM, Stronks K, van Montfrans G. Lipid profile in a Triethnic population in the Netherlands: the Sunset study. J Hypertens. 2009;27:S324.

    Google Scholar 

  7. Dekker LH, Nicolaou M, van der A DL, Busschers WB, Brewster LM, Snijder MB, Stronks K, van Valkengoed IG. Sex differences in the association between serum ferritin and fasting glucose in type 2 diabetes among South Asian Surinamese, African Surinamese, and ethnic Dutch: the population-based SUNSET study. Diabetes Care. 2013;36:965–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Brewster LM, Mairuhu G, Bindraban NR, Koopmans RP, Clark JF, van Montfrans GA. Creatine kinase activity is associated with blood pressure. Circulation. 2006;114:2034–9.

    Article  CAS  PubMed  Google Scholar 

  9. Karthikeyan G, Teo KK, Islam S, McQueen MJ, Pais P, Wang X, Sato H, Lang CC, Sitthi-Amorn C, Pandey MR, Kazmi K, Sanderson JE, Yusuf S. Lipid profile, plasma apolipoproteins, and risk of a first myocardial infarction among Asians: an analysis from the INTERHEART study. J Am Coll Cardiol. 2009;53:244–53.

    Article  CAS  PubMed  Google Scholar 

  10. Okin PM, Kjeldsen SE, Dahlöf B, Devereux RB. Racial differences in incident heart failure during antihypertensive therapy. Circ Cardiovasc Qual Outcomes. 2011;4:157–64.

    Article  PubMed  Google Scholar 

  11. Joshi P, Islam S, Pais P, Reddy S, Dorairaj P, Kazmi K, Pandey MR, Haque S, Mendis S, Rangarajan S, Yusuf S. Risk factors for early myocardial infarction in south Asians compared with individuals in other countries. JAMA. 2007;297:286–94.

    Article  CAS  PubMed  Google Scholar 

  12. Jolly S, Vittinghoff E, Chattopadhyay A, Bibbins-Domingo K. Higher cardiovascular disease prevalence and mortality among younger blacks compared to whites. Am J Med. 2010;123:811–8.

    Article  PubMed  Google Scholar 

  13. Opie LH, Seedat YK. Hypertension in sub-Saharan African populations. Circulation. 2005;112:3562–8.

    Article  PubMed  Google Scholar 

  14. Haan YC, van Montfrans GA, Brewster LM. The high creatine kinase phenotype is hypertension- and obesity-prone. J Clin Hypertens. 2015;17:322.

    Article  Google Scholar 

  15. Eastwood SV, Tillin T, Chaturvedi N, Hughes AD. Ethnic differences in associations between blood pressure and stroke in south Asian and European men. Hypertension. 2015;66:481–8.

    Article  CAS  PubMed  Google Scholar 

  16. Brewster LM, Seedat YK. Why do hypertensive patients of African ancestry respond better to calcium blockers and diuretics than to ACE inhibitors and β-adrenergic blockers? A systematic review. BMC Med. 2013;11:141.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Brewster LM, van Montfrans GA, Kleijnen J. Systematic review: antihypertensive drug therapy in black patients. Ann Intern Med. 2004;141:614–27.

    Article  PubMed  Google Scholar 

  18. Oudman I, Kewalbansingh PV, van Valkengoed I, Zwinderman AH, Clark JF, van Montfrans GA, Brewster LM. Creatine kinase is associated with failure of hypertension treatment. J Hypertens. 2013;31:1025–31.

    Article  CAS  PubMed  Google Scholar 

  19. Brewster LM, van Montfrans GA, Oehlers GP, Seedat YK. Systematic review: antihypertensive drug therapy in patients of African and south Asian ethnicity. Intern Emerg Med. 2016;11:355–74.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Kizer JR, Arnett DK, Bella JN, Paranicas M, Rao DC, Province MA, Oberman A, Kitzman DW, Hopkins PN, Liu JE, Devereux RB. Differences in left ventricular structure between black and white hypertensive adults: the Hypertension Genetic Epidemiology Network study. Hypertension. 2004;43:1182–8.

    Article  CAS  PubMed  Google Scholar 

  21. Spencer CG, Beevers DG, Lip GY. Ethnic differences in left ventricular size and the prevalence of left ventricular hypertrophy among hypertensive patients vary with electrocardiographic criteria. J Hum Hypertens. 2004;18:631–6.

    Article  CAS  PubMed  Google Scholar 

  22. Mohan V, Seedat YK, Pradeepa R. The rising burden of diabetes and hypertension in southeast Asian and African regions: need for effective strategies for prevention and control in primary health care settings. Int J Hypertens. 2013;2013:409083.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Parati G, Steptoe A. Stress reduction and blood pressure control in hypertension: a role for transcendental meditation? J Hypertens. 2004;22:2057–60.

    Article  CAS  PubMed  Google Scholar 

  24. Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, Obarzanek E, Conlin PR, Miller ER 3rd, Simons-Morton DG, Karanja N, Lin PH, DASH-Sodium Collaborative Research Group. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med. 2001;344:3–10.

    Article  CAS  PubMed  Google Scholar 

  25. Graudal N, Jürgens G. The blood pressure sensitivity to changes in sodium intake is similar in Asians, Blacks and Whites. An analysis of 92 randomized controlled trials. Front Physiol. 2015;6:157.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Chan Q, Stamler J, Elliott P. Dietary factors and higher blood pressure in African-Americans. Curr Hypertens Rep. 2015;17:10.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  27. Jessani S, Hatcher J, Chaturvedi N, Jafar TH. Effect of low vs. high dietary sodium on blood pressure levels in a normotensive Indo-Asian population. Am J Hypertens. 2008;21:1238–44.

    Article  CAS  PubMed  Google Scholar 

  28. Patki PS, Singh J, Gokhale SV, Bulakh PM, Shrotri DS, Patwardhan B. Efficacy of potassium and magnesium in essential hypertension: a double-blind, placebo controlled, crossover study. BMJ. 1990;301:521–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Subramanian H, Soudarssanane MB, Jayalakshmy R, Thiruselvakumar D, Navasakthi D, Sahai A, Saptharishi L. Non-pharmacological interventions in hypertension: a community-based cross-over randomized controlled trial. Indian J Community Med. 2011;36:191–6.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Selvamurthy W, Sridharan K, Ray US, Tiwary RS, Hegde KS, Radhakrishan U, Sinha KC. A new physiological approach to control essential hypertension. Indian J Physiol Pharmacol. 1998;42:205–13.

    CAS  PubMed  Google Scholar 

  31. Graudal N, Jürgens G, Baslund B, Alderman MH. Compared with usual sodium intake, low- and excessive-sodium diets are associated with increased mortality: a meta-analysis. Am J Hypertens. 2014;27:1129–37.

    Article  CAS  PubMed  Google Scholar 

  32. Kalogeropoulos AP, Georgiopoulou VV, Murphy RA, Newman AB, Bauer DC, Harris TB, Yang Z, Applegate WB, Kritchevsky SB. Dietary sodium content, mortality, and risk for cardiovascular events in older adults: the health, aging, and body composition (Health ABC) study. JAMA Intern Med. 2015;175:410–9.

    Article  PubMed  PubMed Central  Google Scholar 

  33. USA Guideline Diet. U.S. Department of Agriculture and U.S. Department of Health and Human Services: Dietary Guidelines for Americans, 2010. 7th ed. Washington, DC: U.S. Government Printing Office; 2010.

    Google Scholar 

  34. Park IU, Taylor AL. Race and ethnicity in trials of antihypertensive therapy to prevent cardiovascular outcomes: a systematic review. Ann Fam Med. 2007;5:444–52.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011.

    Google Scholar 

  36. Association of Black Cardiologists (ABC) Candesartan Study Group. Evaluation of candesartan Cilexetil in black patients with systemic hypertension: the ABC trial. Heart Dis. 2000;2:392–9.

    Google Scholar 

  37. Conlin PR, Erlinger TP, Bohannon A, Miller ER III, Appel LJ, Svetkey LP, Moore TJ. The DASH diet enhances the blood pressure response to losartan in hypertensive patients. Am J Hypertens. 2003;16:337–42.

    Article  CAS  PubMed  Google Scholar 

  38. Dean G, Louw S, Hersch C, Kirsten HO, Brereton DN, Finnemore L, Dewar J. A double-blind trial in hypertension comparing Baycaron (FBA 1500), hydrochlorothiazide and placebo. S Afr Med J. 1971;45:323.

    CAS  PubMed  Google Scholar 

  39. Drayer JI, Weber MA. Monotherapy of essential hypertension with a converting-enzyme inhibitor. Hypertension. 1983;5:108–13.

    Article  Google Scholar 

  40. Fadayomi MO, Akinroye KK, Ajao RO, Awosika LA. Monotherapy with nifedipine for essential hypertension in adult blacks. J Cardiovasc Pharmacol. 1986;8:466–9.

    Article  CAS  PubMed  Google Scholar 

  41. Fiddes R, Heym H, Hilty W, Lewin AJ, Codispoti J, McNally C, Stokes A, Gilderman L. Blood pressure control with diltiazem XR, a novel extended-release formulation of diltiazem HCl, in mature and elderly hypertensive patients. Clin Ther. 1994;16:209–21.

    CAS  PubMed  Google Scholar 

  42. Flack JM, Saunders E, Gradman A, Kraus WE, Lester FM, Pratt JH, Alderman M, Green S, Vargas R, Espenshade M, Ceesay P, Alexander J Jr, Goldberg A. Antihypertensive efficacy and safety of losartan alone and in combination with hydrochlorothiazide in adult African Americans with mild to moderate hypertension. Clin Ther. 2001;23:1193–208.

    Article  CAS  PubMed  Google Scholar 

  43. Flack JM, Oparil S, Pratt JH, Roniker B, Garthwaite S, Kleiman JH, Yang Y, Krause SL, Workman D, Saunders E. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J Am Coll Cardiol. 2003;41:1148–55.

    Article  CAS  PubMed  Google Scholar 

  44. Frishman WH, Burris JF, Mroczek WJ, Weir MR, Alemayehu D, Simon JS, Chen SY, Bryzinski BS. First-line therapy option with low-dose bisoprolol fumarate and low-dose hydrochlorothiazide in patients with stage I and stage II systemic hypertension. J Clin Pharmacol. 1995;35:182–8.

    Article  CAS  PubMed  Google Scholar 

  45. Humphreys GS, Delvin DG. Ineffectiveness of propranolol in hypertensive Jamaicans. Br Med J. 1968;2:601–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Lewin A, Punzi H, Luo X, Stapff M. Nebivolol monotherapy for patients with systolic stage II hypertension: results of a randomized, placebo-controlled trial. Clin Ther. 2013;35:142–52.

    Article  CAS  PubMed  Google Scholar 

  47. Materson BJ, Reda DJ, Cushman WC, Massie BM, Freis ED, Kochar MS, Hamburger RJ, Fye C, Lakshman R, Gottdiener J, Ramirez EA, Henderson WG. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on antihypertensive agents. N Engl J Med. 1993;328:914–21.

    Article  CAS  PubMed  Google Scholar 

  48. Materson BJ, Reda DJ, Cushman WC. Department of Veterans Affairs single-drug therapy of hypertension study. Revised figures and new data. Am J Hypertens. 1995;8:189–92.

    Article  CAS  PubMed  Google Scholar 

  49. Moser M, Lunn J. Responses to captopril and hydrochlorothiazide in black patients with hypertension. Clin Pharmacol Ther. 1982;32:307–12.

    Article  CAS  PubMed  Google Scholar 

  50. Moser M, Lunn J, Nash DT, Burris JF, Winer N, Simon G, Vlachakis ND. Nitrendipine in the treatment of mild to moderate hypertension. J Cardiovasc Pharmacol. 1984;6(Suppl 7):S1085–9.

    PubMed  Google Scholar 

  51. Opie LH, Muller FO, Myburgh DP, Rosendorff C, Sareli P, Seedat YK, Weich DJ, Luus HG. Efficacy and tolerability of nisoldipine coat-core formulation in the treatment of essential hypertension: the South African Multicenter ANCHOR study. Am J Hypertens. 1997;10:250–60.

    Article  CAS  PubMed  Google Scholar 

  52. Salako LA, Falase AO, Aderounmu AF. Placebo-controlled, double-blind clinical trial of alprenolol in African hypertensive patients. Curr Med Res Opin. 1979;6:358–63.

    Article  CAS  PubMed  Google Scholar 

  53. Saunders E, Smith WB, DeSalvo KB, Sullivan WA. The efficacy and tolerability of nebivolol in hypertensive African American patients. J Clin Hypertens. 2007;9:866–75.

    Article  CAS  Google Scholar 

  54. Seedat YK. Trial of atenolol and chlorthalidone for hypertension in black south Africans. Br Med J. 1980;281:1241–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Seedat YK. An evaluation of debrisoquine and mefruside in the treatment of hypertension in African and Indian patients. Curr Med Res Opin. 1980;7:68–72.

    Article  CAS  PubMed  Google Scholar 

  56. Stein CM, Neill P, Kusemamuriwo T. Antihypertensive effects of low doses of hydrochlorothiazide in hypertensive black Zimbabweans. Int J Cardiol. 1992;37:231–5.

    Article  CAS  PubMed  Google Scholar 

  57. Davis BR, Blaufox MD, Hawkins CM, Langford HG, Oberman A, Swencionis C, Wassertheil-Smoller S, Wylie-Rosett J, Zimbaldi N. Trial of antihypertensive interventions and management. Design, methods, and selected baseline results. Control Clin Trials. 1989;10:11–30.

    Article  CAS  PubMed  Google Scholar 

  58. Wassertheil-Smoller S, Davis BR, Oberman AS, Blaufox MD, Langford HG, Wylie-Rosett J, Hawkins M, Zimbaldi N. The Taim study: sex-race differences in effects of diet and drugs on cardiovascular risk. Cardiovasc Risk Factors. 1991;1:3–11.

    Google Scholar 

  59. Neaton JD, Grimm RH Jr, Prineas RJ, Stamler J, Grandits GA, Elmer PJ, Cutler JA, for the TOMHS Research Group. Treatment of mild hypertension study. Final results. Treatment of mild hypertension study research group. JAMA. 1993;270:713–24.

    Article  CAS  PubMed  Google Scholar 

  60. Grimm RH, Grandits GA, Flack JM. Are black and white hypertensives really different? ABC Digest Urban Cardiol. 1997;4:10–6.

    Google Scholar 

  61. Reisin E, Weir MR, Falkner B, Hutchinson HG, Anzalone DA, Tuck ML, for the treatment in obese patients with hypertension (TROPHY) Study Group. Lisinopril versus hydrochlorothiazide in obese hypertensive patients: a multicenter placebo-controlled trial. Hypertension. 1997;30:140–5.

    Article  CAS  PubMed  Google Scholar 

  62. Venter CP, Joubert PH, Venter HL, Muntingh GL, du Plooy WJ. Penbutolol in the treatment of mild to moderate essential hypertension in black south Africans. J Clin Pharmacol. 1990;30:533–7.

    Article  CAS  PubMed  Google Scholar 

  63. Venter CP, Muntingh GL, Venter HL, du Plooy WJ. The effect of xipamide on mild-moderate hypertension in black south Africans—results of a clinical trial. Med Sci Res. 1991;19:217–8.

    Google Scholar 

  64. Venter CP, Venter HL, Muntingh GL. [The effect of enalapril and prazosin on mild to moderate hypertension in black South Africans]. S Afr Med J. 1991;80:324–6.

    Google Scholar 

  65. Weir MR, Chrysant SG, McCarron DA, Canossa-Terris M, Cohen JD, Gunter PA, Lewin AJ, Mennella RF, Kirkegaard LW, Hamilton JH, Weinberger MH, Weder AB. Influence of race and dietary salt on the antihypertensive efficacy of an angiotensin-converting enzyme inhibitor or a calcium channel antagonist in salt-sensitive hypertensives. Hypertension. 1998;31:1088–96.

    Article  CAS  PubMed  Google Scholar 

  66. Weir MR, Saunders E. Renin status does not predict the anti-hypertensive response to angiotensin-converting enzyme inhibition in African-Americans. Trandolapril multicenter study group. J Hum Hypertens. 1998;12:189–94.

    Article  CAS  PubMed  Google Scholar 

  67. The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension. J Clin Epidemiol. 1988;41:1197–208.

    Article  Google Scholar 

  68. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:3255–64.

    Article  Google Scholar 

  69. The Systolic Hypertension in the Elderly Program Cooperative Research Group. Implications of the systolic hypertension in the elderly program. Hypertension. 1993;21:335–43.

    Article  Google Scholar 

  70. Dahlof B, Devereux R, de Faire U, Fyhrquist F, Hedner T, Ibsen H, Julius S, Kjeldsen S, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H. The Losartan Intervention for Endpoint reduction (LIFE) in hypertension study: rationale, design, and methods. Am J Hypertens. 1997;10:705–13.

    Article  CAS  PubMed  Google Scholar 

  71. Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Dahlof B. Baseline characteristics in relation to electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan intervention for endpoint reduction (LIFE) in hypertension study. Hypertension. 2000;36:766–73.

    Article  CAS  PubMed  Google Scholar 

  72. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995–1003.

    Article  CAS  PubMed  Google Scholar 

  73. Julius S, Alderman MH, Beevers G, Dahlof B, Devereux RB, Douglas JG, Edelman JM, Harris KE, Kjeldsen SE, Nesbitt S, Randall OS, Wright JT. Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy: the LIFE study. J Am Coll Cardiol. 2004;43:1047–55.

    Article  PubMed  Google Scholar 

  74. Gassman JJ, Greene T, Wright JT Jr, Agodoa L, Bakris G, Beck GJ, Douglas J, Jamerson K, Lewis J, Kutner M, Randall OS, Wang SR. Design and statistical aspects of the African American study of kidney disease and hypertension (AASK). J Am Soc Nephrol. 2003;14:S154–65.

    Article  PubMed  Google Scholar 

  75. Agodoa LY, Appel L, Bakris GL, Beck G, Bourgoignie J, Briggs JP, For the African American Study of Kidney Disease and Hypertension (AASK) Study Group. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA. 2001;285:2719–28.

    Article  CAS  PubMed  Google Scholar 

  76. Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, For the African American Study of Kidney Disease and Hypertension Study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002;288:2421–31.

    Article  CAS  PubMed  Google Scholar 

  77. Davis BR, Cutler JA, Gordon DJ, Furberg CD, Wright JT Jr, Cushman WC, Grimm RH, LaRosa J, Whelton PK, Perry HM, Alderman MH, Ford CE, Oparil S, Francis C, Proschan M, Pressel S, Black HR, Hawkins CM. Rationale and design for the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT). Am J Hypertens. 1996;9:342–60.

    Article  CAS  PubMed  Google Scholar 

  78. Grimm RH Jr, Margolis KL, Papademetriou VV, Cushman WC, Ford CE, Bettencourt J, Alderman MH, Basile JN, Black HR, DeQuattro VV, Eckfeldt J, Hawkins CM, Perry HM Jr, Proschan M. Baseline characteristics of participants in the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT). Hypertension. 2001;37:19–27.

    Article  CAS  PubMed  Google Scholar 

  79. ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA. 2000;283:1967–75.

    Article  Google Scholar 

  80. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA. 2002;288:2981–97.

    Article  Google Scholar 

  81. Norris K, Bourgoigne J, Gassman J, Hebert L, Middleton J, Phillips RA, Randall O, Rostand S, Sherer S, Toto RD, Wright JT Jr, Wang X, Greene T, Appel LJ, Lewis J, AASK Study Group. Cardiovascular outcomes in the African American study of kidney disease and hypertension (AASK) trial. Am J Kidney Dis. 2006;48:739–51.

    Article  CAS  PubMed  Google Scholar 

  82. Zanchetti A, Julius S, Kjeldsen S, McInnes GT, Hua T, Weber M, Laragh JH, Plat F, Battegay E, Calvo-Vargas C, Cieśliński A, Degaute JP, Holwerda NJ, Kobalava J, Pedersen OL, Rudyatmoko FP, Siamopoulos KC, Störset O. Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: an analysis of findings from the VALUE trial. J Hypertens. 2006;24:2163–8.

    Article  CAS  PubMed  Google Scholar 

  83. Jamerson K, Champion A, Zhou Q, Pepine C, et al. Am J Hypertens. 2005;18(5 part 2):109A. Abstract P286.

    Article  Google Scholar 

  84. Weir MR, Bakris GL, Weber MA, Dahlof B, Devereux RB, Kjeldsen SE, Pitt B, Wright JT, Kelly RY, Hua TA, Hester RA, Velazquez E, Jamerson KA. Renal outcomes in hypertensive Black patients at high cardiovascular risk. Kidney Int. 2012;81:568–76.

    Article  CAS  PubMed  Google Scholar 

  85. Kizer JR, Dahlof B, Kjeldsen SE, Julius S, Beevers G, De Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, Wachtell K, Edelman JM, Snapinn SM, Harris KE, Devereux RB. Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan intervention for endpoint reduction in hypertension study. Hypertension. 2005;45:46–52.

    Article  CAS  PubMed  Google Scholar 

  86. Wright JT Jr, Dunn JK, Cutler JA, Davis BR, Cushman WC, Ford CE, Haywood LJ, Leenen FHH, Margolis KL, Papademetriou V, Probstfield JL, Whelton PK, Habib GB. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA. 2005;293:1595–608.

    Article  CAS  PubMed  Google Scholar 

  87. Okin PM, Kjeldsen SE, Julius S, Dahlöf B, Devereux RB. Racial differences in sudden cardiac death among hypertensive patients during antihypertensive therapy: the LIFE study. Heart Rhythm. 2012;9:531–7.

    Article  PubMed  Google Scholar 

  88. Yamal JM, Oparil S, Davis BR, Alderman MH, Calhoun DA, Cushman WC, Fendley HF, Franklin SS, Habib GB, Pressel SL, Probstfield JL, Sastrasinh S. Stroke outcomes among participants randomized to chlorthalidone, amlodipine or lisinopril in ALLHAT. J Am Soc Hypertens. 2014;8:808–19.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  89. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT-LLT). JAMA. 2002;288(23):2998–3007.

    Article  Google Scholar 

  90. Akat PB, Bapat TR, Murthy MB, Karande VB, Burute SR. Comparison of the efficacy and tolerability of telmisartan and enalapril in patients of mild to moderate essential hypertension. Indian J Pharmacol. 2010;42:153–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  91. Ali G, Kamili MMA, Kumar M, Rashid S, Dhar S, Pandita VR, Wadhwa MB. Efficacy & tolerability of losartan compared with amlodipine in the treatment of essential hypertension. JK Pract. 2001;8:140–2.

    Google Scholar 

  92. Bhatia J, Mahajan P, Sikka M, Kalra OP. Effect of various antihypertensive drugs on plasma fibrinogen levels in patients with essential hypertension. Indian J Med Sci. 2001;55:491.

    CAS  PubMed  Google Scholar 

  93. Devi P, Xavier D, Sigamani A, Pandey S, Thomas T, Murthy S, Sharma K, Bosco B, Mehta K, Joshi S, Gupta R, Singh G, Hiremath J, Ds C, Nambiar A, Pais P. Effect of fixed dose combinations of metoprolol and amlodipine in essential hypertension: MARS--a randomized controlled trial. Blood Press Suppl. 2011;2:5–12.

    Article  PubMed  CAS  Google Scholar 

  94. Goyal J, Khan ZY, Upadhyaya P, Goyal B, Jain S. Comparative study of high dose mono-therapy of amlodipine or telmisartan, and their low dose combination in mild to moderate hypertension. J Clin Diagn Res. 2014;8:HC08–11.

    PubMed  PubMed Central  Google Scholar 

  95. Jalal S, Sofi FA, Abass SM, Alai MS, Bhat MA, Rather HA, Lone NA, Siddiqi MA. Effect of amlodipine and lisinopril on microalbuminuria in patients with essential hypertension: a prospective study. Indian J Nephrol. 2010;20:15–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  96. Jamali S, Mashori GR, Maher Z, Khan M. Comparison of candesartan cilexetil and atenolol in essential hypertensive patients. Med Chan. 2008;14:28–31.

    Google Scholar 

  97. Joglekar SJ, Jaguste V, Nanivadekar AS. Prazosin GITS vs atenolol in patients with hypertension and normal lipid profile: a randomized, controlled multicenter study. Hyderabad Hypertension Study Group. J Assoc Physicians India. 1998;(Suppl 1):41–51.

    Google Scholar 

  98. Misra KP, Joglekar SJ, Mukherjee S, Nanivadekar AS. Prazosin GITS vs sustained release nifedipine in patients with hypertension and abnormal lipid profile: a randomized, controlled, multicenter study. Madras Hypertension Study Group. J Assoc Physicians India. 1998;(Suppl 1):30–40.

    Google Scholar 

  99. Nandeesha H, Pavithran P, Madanmohan T. Effect of antihypertensive therapy on serum lipids in newly diagnosed essential hypertensive men. Angiology. 2009;60:217–20.

    Article  CAS  PubMed  Google Scholar 

  100. Pareek A, Karnik N, Salagre SB, Zawar SD, Joglekar VK, Chandurkar N, Naik GS. Clinical effectiveness of low-dose chlorthalidone (6.25 mg) + atenolol combination in stage I hypertensive patients: a multicenter, randomized, controlled study. Curr Med Res Opin. 2008;24:1771–9.

    Article  CAS  PubMed  Google Scholar 

  101. Raja M, Shukla AK, Mehani R, Agnihotri A. Comparative study of telmisartan and ramipril as an antihypertensive in mild to moderate hypertension. Natl J Physiol Pharm Pharmacol. 2016;6(5):388–93.

    Article  CAS  Google Scholar 

  102. Satia MC, Shukla ML, Goyal RK. Comparative effects of atenolol versus nifedipine on serum lipids and other biochemical parameters in diabetic and non-diabetic hypertensive subjects. Indian J Physiol Pharmacol. 1995;39:237–41.

    CAS  PubMed  Google Scholar 

  103. Shobha JC, Kumar TR, Raju BS, Kamath S, Rao M, Harwal, Babeu A, Bhaduri J. Evaluation of efficacy and safety of losartan potassium in the treatment of mild to moderate hypertension as compared to enalapril maleate. J Assoc Physicians India. 2000;48:497–500.

    CAS  PubMed  Google Scholar 

  104. Sumbria M, Negi PC, Sahai AK, Kaundal PK. To compare the effect of Telmisartan with metoprolol on arterial stiffness in hypertension: prospective randomized parallel group trial. Indian Heart J. 2014;66:415–21.

    Article  PubMed  PubMed Central  Google Scholar 

  105. Sundar S, Rajan AG, Somani PN, Kumar K. The effects of antihypertensive agents on the quality of life in Indian hypertensives. Acta Cardiol. 1991;46:227–35.

    CAS  PubMed  Google Scholar 

  106. NCD Global Monitoring Framework. http://www.who.int/nmh/global_monitoring_framework/en/. Accessed 1 Oct 2017.

  107. He FJ, MacGregor GA. Blood pressure is the most important cause of death and disability in the world. Eur Heart J Suppl. 2007;9:B23–8.

    Article  Google Scholar 

  108. Roth GA, Nguyen G, Forouzanfar MH, Mokdad AH, Naghavi M, Murray CJ. Estimates of global and regional premature cardiovascular mortality in 2025. Circulation. 2015;132:1270–82.

    Article  PubMed  Google Scholar 

  109. Lonn EM, Bosch J, López-Jaramillo P, Zhu J, Liu L, Pais P, Diaz R, Xavier D, Sliwa K, Dans A, Avezum A, Piegas LS, Keltai K, Keltai M, Chazova I, Peters RJ, Held C, Yusoff K, Lewis BS, Jansky P, Parkhomenko A, Khunti K, Toff WD, Reid CM, Varigos J, Leiter LA, Molina DI, McKelvie R, Pogue J, Wilkinson J, Jung H, Dagenais G, Yusuf S, HOPE-3 Investigators. Blood-pressure lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med. 2016;374:2009–20.

    Article  CAS  PubMed  Google Scholar 

  110. Hippisley-Cox J, Coupland C, Robson J, Brindle P. Derivation, validation, and evaluation of a new QRISK model to estimate lifetime risk of cardiovascular disease: cohort study using QResearch database. BMJ. 2010;341:c6624.

    Article  PubMed  PubMed Central  Google Scholar 

  111. Brindle P, May M, Gill P, Cappuccio F, D'Agostino R Sr, Fischbacher C, Ebrahim S. Ethrisk primary prevention of cardiovascular disease: a web-based risk score for seven British black and minority ethnic groups. Heart. 2006;92:1595–602.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  112. Leenen FH, Dumais J, McInnis NH, Turton P, Stratychuk L, Nemeth K, Moy Lum-Kwong M, Fodor G. Results of the Ontario survey on the prevalence and control of hypertension. CMAJ. 2008;178:1441–9.

    Article  PubMed  PubMed Central  Google Scholar 

  113. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, MacLaughlin EJ, Muntner P, Ovbiagele B, Smith SC Jr, Spencer CC, Stafford RS, Taler SJ, Thomas RJ, Williams KA Sr, Williamson JD, Wright JT Jr. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2017. pii: S0735-1097(17)41519-1.

    Google Scholar 

  114. SPRINT Research Group, Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff DC Jr, Fine LJ, Cutler JA, Cushman WC, Cheung AK, Ambrosius WT. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373:2103–16.

    Article  CAS  Google Scholar 

  115. Lonn EM, Yusuf S. Should patients with cardiovascular risk factors receive intensive treatment of hypertension to <120/80 mmHg target? An antagonist view from the HOPE-3 Trial (Heart Outcomes Evaluation-3). Circulation. 2016;134(18):1311–3.

    Article  PubMed  Google Scholar 

  116. Flack JM, Sica DA, Bakris G, Brown AL, Ferdinand KC, Grimm RH Jr, Hall WD, Jones WE, Kountz DS, Lea JP, Nasser S, Nesbitt SD, Saunders E, Scisney-Matlock M, Jamerson KA. Management of high blood pressure in blacks: an update of the international society on hypertension in blacks consensus statement. Hypertension. 2010;56:780–800.

    Article  CAS  PubMed  Google Scholar 

  117. Flack JM, Bhatt DL, Kandzari DE, Brown D, Brar S, Choi JW, D’Agostino R, East C, Katzen BT, Lee L, Leon MB, Mauri L, O’Neill WW, Oparil S, Rocha-Singh K, Townsend RR, Bakris G, SYMPLICITY HTN-3 Investigators. An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and non-African Americans in the SYMPLICITY HTN-3 trial. J Am Soc Hypertens. 2015;9:769–79.

    Article  PubMed  Google Scholar 

  118. Angell SY, De Cock KM, Frieden TR. A public health approach to global management of hypertension. Lancet. 2015;385:825–7.

    Article  PubMed  PubMed Central  Google Scholar 

  119. Oparil S, Melino M, Lee J, Fernandez V, Heyrman R. Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: the TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study. Clin Ther. 2010;32:1252–69.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Amsterdam Institute for Global Health and Development (AIGHD), University of Amsterdam, Amsterdam, The Netherlands

    Lizzy M. Brewster

  2. Department of Internal Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands

    Gert A. van Montfrans

  3. Nelson R Mandela School of Medicine, Faculty of Health Sciences, University of KwaZulu Natal, Durban, South Africa

    Yackoob K. Seedat

Authors
  1. Lizzy M. Brewster
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gert A. van Montfrans
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yackoob K. Seedat
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lizzy M. Brewster .

Editor information

Editors and Affiliations

  1. Department of Clinical and Experimental Medicine, University of Florence, Firenze, Italy

    Pietro Amedeo Modesti

  2. University of Warwick, Warwick Medical School, and University, Hospitals Coventry and Warwickshire, NHS Trust, Coventry, UK

    Francesco P. Cappuccio

  3. Istituto Auxologico Italiano, IRCCS, Department of Cardiovascular, Neural and Metabolic Sciences, San Luca Hospital, Milan, Italy

    Gianfranco Parati

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Brewster, L.M., van Montfrans, G.A., Seedat, Y.K. (2018). Antihypertensive Drug Therapy in Patients of African and South Asian Ethnicity: A Systematic Review. In: Modesti, P., Cappuccio, F., Parati, G. (eds) Ethnic Diversities, Hypertension and Global Cardiovascular Risk. Updates in Hypertension and Cardiovascular Protection. Springer, Cham. https://doi.org/10.1007/978-3-319-93148-7_20

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-93148-7_20

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-93147-0

  • Online ISBN: 978-3-319-93148-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation